NCT01110044撤回2 期
Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Immunogenicity with respect to components of the study vaccines.
研究概览
简要总结
The purpose of the study is to evaluate the safety and immunogenicity of a birth dose of GSK Biologicals' reduced-antigen-content tri-component pertussis (251154) vaccine followed by routine paediatric vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 2 Days 至 5 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes that their parent(s)/LAR(s) can and will comply with the requirements of the protocol.
- •Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •A male or female infant between, and including, 2 and 5 days of age at the time of randomisation.
- •Subjects who are born after an uncomplicated gestation period of 36 to 42 weeks inclusive.
- •Subjects born to a mother seronegative for hepatitis B surface antigen.
- •Subjects with a birth weight >= 2.5 kg.
- •Subjects with a 5-minute Apgar score >=
- •Healthy subjects as established by medical history and clinical examination
排除标准
- •Use of any investigational or non-registered product other than the study vaccines since birth, or planned use during the study period.
- •Born to a mother known or suspected to be seropositive for HIV.
- •Family history of congenital or hereditary immunodeficiency.
- •Children in care..
- •Neonatal jaundice requiring systemic treatment.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •Administration of any vaccine since birth or planned administration during the study period with the exception of inactivated influenza vaccines.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •History of seizures or progressive neurological disease.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •Major congenital defects or serious chronic illness, including perinatal brain damage.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •Current febrile illness or temperature >= 38.5°C on oral or axillary setting, or >= 39.0°C on rectal setting, or other moderate to severe illness within 24 hours of study vaccine administration.
结局指标
主要结局
Immunogenicity with respect to components of the study vaccines.
时间窗: One month after the third dose of primary vaccination.
次要结局
- Immunogenicity with respect to components of the study vaccines (on secondary readouts).(One month after booster vaccination.)
- Occurrence of solicited local and general symptoms (on secondary readouts).(On Day 0-Day 3 after each dose of primary and booster vaccination.)
- Occurrence of unsolicited adverse events (on secondary readouts).(On Day 0-Day 30 after each vaccination.)
- Occurrence of serious adverse events (on secondary readouts).(From enrolment up to study end.)
研究者
相似试验
已完成
3 期
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsInfections, StreptococcalNCT00390910GlaxoSmithKline286
撤回
3 期
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 YearsInfections, PapillomavirusNCT02082639GlaxoSmithKline
已完成
3 期
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT VaccineAcellular PertussisTetanusDiphtheriaNCT00452686GlaxoSmithKline660
已完成
3 期
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenRubellaMeaslesMumpsVaricellaNCT01506193GlaxoSmithKline716
已完成
1 期
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixInfluenzaNCT00693706GlaxoSmithKline200